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Abstract. Recurrence is a common complication observed 
during cutaneous squamous cell carcinoma (cSCC) treatment; 
however, biomarkers for predicting recurrence in cSCC remain 
unknown. The present study aimed to investigate the predictive 
value of axis inhibition protein 2 (AXIN2) and SNAIL expres-
sion in cSCC recurrence. AXIN2 and SNAIL expression was 
evaluated using immunohistochemistry in 111 cSCC tissue 
samples obtained from 18 patients who presented recurrence 
(recurrence interval, 1-91 months) and 93 patients who did not 
experience recurrence following Mohs micrographic surgery 
(MMS) during the follow-up period (156 months). Nomogram 
construction was performed using patients' clinicopathological 
characteristics and AXIN2 and SNAIL protein expression. 
The results demonstrated that high AXIN2 (histoscore >100) 
and SNAIL (histoscore >100) expression was detected in 35 
and 44 cSCC tissues, respectively. Furthermore, the expression 
levels of AXIN2 and SNAIL were significantly associated in 
patients with cSCC (P=0.001). AXIN2 and SNAIL expression 
levels were significantly associated with tumor size (P=0.021 
and P=0.044, respectively) and recurrence of cSCC (P=0.017 
and P=0.042, respectively). In addition, the results of the 
Kaplan-Meier curve analysis revealed that recurrence-free 
survival was significantly associated with tumor size 
(P=0.025), differentiation status (P<0.001), AXIN2 expression 
(P=0.001) and SNAIL expression (P=0.001). Furthermore, 
the results of the multivariate analysis demonstrated that 
age (P=0.043), AXIN2 expression (P=0.001) and SNAIL 
expression (P=0.045) were independent risk factors for cSCC 
recurrence in the present cohort. A nomogram for predicting 
the 1-, 2-, 3-, and 5-year recurrence-free survival was devel-
oped for patients with cSCC by including independent risk 
factors with a concordance index of 0.75. The results suggested 
that high AXIN2 and SNAIL expression may be considered 
as potential risk factors for cSCC recurrence. This nomogram 
may therefore be useful to assess the probability of recurrence 
in patients with cSCC following MMS.
Introduction
The occurrence of cutaneous squamous cell carcinoma (cSCC), 
which is the second most common type of non-melanoma skin 
cancer in Korea, has markedly increased in numerous coun-
tries. The age‑standardized incidence rate of squamous cell 
carcinoma during 1999-2014 in Korea was 1.34 per 100,000 
people for men, and 1.04 per 100,000 for women. The average 
annual percentage change (AAPC) of cSCC has increased both 
in women [AAPC, 6.8 (95% CI, 5.3 to 8.4)] and men [AAPC, 
3.3 (95% CI, 2.6 to 4.0)] (1,2). Surgical treatment is curative 
in most cases of cSCC; in particular, Mohs micrographic 
surgery (MMS) has become an common treatment option for 
various types of cutaneous neoplasm, including cSCC (3). As 
a standard form of tissue-conservative skin cancer surgery, 
MMS ensures clearance of pathological margins via intraop-
erative histopathologic interpretation using the fresh‑frozen 
tissue technique; therefore, MMS leads to a lower recurrence 
rate compared with other therapies that use conventional 
wide excision (3). However, certain patients that experience 
recurrence following MMS require adjuvant therapy (3-5). 
Since adjuvant therapy can cause numerous side effects, it is 
crucial to identify a reliable method for assessing the risk of 
recurrence in patients with cSCC following surgery.
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The clinical risk factors for cSCC recurrence include tumor 
invasion depth, size, differentiation status, presence of peri-
neural invasion and location (6). In addition, certain molecular 
biomarkers, including tumor protein 53, cyclin-dependent 
kinase inhibitor 2A, telomerase reverse transcriptase gene 
(TERT) and programmed cell death ligand 1 (PD-L1) have 
been considered as potential factors involved in cSCC progres-
sion. In particular, TERT promoter mutations and increased 
PD-L1 expression have been considered as molecular risk 
factors for cSCC recurrence (7-9). However, these predictive 
risk factors are inadequate to properly assess the recurrence 
risk of cSCC with high reproducibility and reliability (5,6).
Epithelial-to-mesenchymal transition (EMT) is a crucial 
process for cancer cell local invasion and metastasis that 
acts through the loss of epithelial properties and the acqui-
sition of a mesenchymal phenotype (10). SNAIL, which is 
a zinc finger transcriptional repressor that functions as a 
crucial EMT regulator by repressing E-cadherin, is associ-
ated with poor prognosis in various types of cancer, such as 
breast cancer, ovarian cancer, and colorectal cancer (11-13). 
In cancer cells, activated canonical Wnt signaling inhibits 
glycogen synthase kinase 3 (GSK-3)-dependent phosphoryla-
tion of SNAIL, which subsequently leads to the inhibition of 
SNAIL degradation, resulting in increased SNAIL protein 
expression (14). Axis inhibition protein 2 (AXIN2), which is 
a GSK-3 scaffolding protein and a downstream target of the 
Wnt signaling pathway, can stabilize nuclear SNAIL expres-
sion through the regulation of a nucleocytoplasmic shuttle for 
GSK-3 (10). Furthermore, it has been reported that AXIN2 
expression is positively correlated with SNAIL expression in 
breast and colon cancer (10,15); however, the predictive value 
of the expression of these proteins in cSCC recurrence remains 
unclear.
This retrospective cohort study aimed to evaluate the 
predictive value of AXIN2 and SNAIL expression in the 
recurrence of cSCC and to determine an accurate risk predic-
tion model for cSCC recurrence.
Materials and methods
Clinical materials. A total of 111 patients with primary 
cSCC who had undergone MMS between january 2000 and 
December 2010 at the Yonsei university Health System, 
Seoul, Korea, were included in the present study. Patients who 
had undergone MMS for recurrent cSCC were excluded from 
this study. Inclusion criteria were listed as follows: Recurrence 
of cSCC was first clinically diagnosed and confirmed histo-
logically and histological pattern of cSCC tissue samples were 
confirmed independently by two pathologists in a blinded 
manner. All tissue samples were obtained from the Department 
of Pathology, Yonsei university Health System, Seoul, Korea. 
The tissue samples were fixed with 4% formalin, embedded 
with paraffin, and stored at room temperature (RT) prior to use. 
This study was approved by the Institutional Review Board 
for Bioethics of Yonsei university Health System, Severance 
Hospital (approval no. IRB 4-2018-0331).
IHC. Formalin-fixed paraffin-embedded tissue samples 
were cut into 4‑µm tissue sections, deparaffinized with 
98.5% xylene and rehydrated with an ethanol gradient series 
(99.9, 80, and 75% ethanol). Antigen retrieval and blocking 
of endogenous peroxidase activity were performed using 
antigen retrieval buffer at 100˚C for 2 min (Dako; Agilent 
Technologies, Inc.) and a mixture of methanol and hydrogen 
peroxide in a 40:1 ratio at RT for 20 min, respectively. Tissue 
sections were incubated with the primary antibodies rabbit 
monoclonal anti-human AXIN2 (Abcam; cat. no. ab109307; 
1:250) and polyclonal rabbit anti-human SNAIL (Abcam; cat. 
no. ab53519; 1:250) at RT for 1 h, as well as REAL EnVision 
HRP Rabbit/Mouse Detection System at RT for 30 min (Dako; 
Agilent Technologies, Inc.; cat. no. K5007; prediluted; Agilent 
Technologies, Inc.) as a secondary antibody, according to the 
manufacturer's protocols. Visualization and counterstaining 
were performed using chromogen 3,3'‑diaminobenzidine 
(Dako; Agilent Technologies, Inc.) and hematoxylin at RT for 
2 min, respectively. Rabbit IgG (Dako; Agilent Technologies, 
Inc.) was used as a negative control.
AXIN2 and SNAIL expression levels were evaluated 
using the weighted histoscore method (16). Briefly, the total 
histoscore was determined based on tissue staining intensity 
and percentage of positively stained cells. Staining intensity 
was scored as 0, 1, 2 and 3 for negative, light brown, brown 
and dark brown staining, respectively. The histoscore was 
calculated as follows: Total histoscore = (0 x percentage of 
negative cells) + (1 x percentage of light-brown cells) + (2 x 
percentage of brown cells) + (3 x percentage of dark brown 
cells). For subsequent analysis, patients were subdivided into 
low and high expression groups with histoscores of 0-100 and 
101-300, respectively. The percent of patients with high or low 
protein expression in each group was calculated and presented 
in Table I.
Statistical analysis. χ2 and Fisher's exact tests were used 
to analyze the associations between AXIN2 and SNAIL 
expression and patients' clinicopathological characteristics. 
Kaplan-Meier survival curves were plotted based on various 
clinical factors and protein expression, and the significance 
was analyzed using the log‑rank test to determine the recur-
rence-free survival of patients with cSCC. Furthermore, the 
strength of associations among various clinical factors and 
cSCC recurrence was analyzed using the Cox proportional 
hazards model. The nomogram for assessment of cSCC recur-
rence risk was constructed using AXIN2 and Snail expression, 
as well as various clinicopathological characteristics such 
as sex, age, lesion site, tumor size, and differentiation, and 
evaluated with the concordance index (c-index) and a cali-
bration plot (17). R package version 3.1.1 (The R Foundation 
for Statistical Computing; http://www.r-project.org) with the 
rms (3.5.0) and eha (2.7.6) packages was used for statistical 
analysis. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient clinicopathological characteristics. In the present 
cohort, 18 (16.2%) patients presented recurrence (interval of 
recurrence, 1-91 months), whereas 93 (83.8%) patients did not 
experience recurrence following MMS during the follow-up 
period of 156 months. Tissue samples were confirmed inde-
pendently by two pathologists in a blinded manner. The age 
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of patients at diagnosis ranged between 30 and 98 years, 
with a median age of 74 years. The patient cohort comprised 
50 (45.0%) men and 61 (55.0%) women, and the tumor size 
ranged from 0.3 cm to 4.5 cm, with a median tumor size of 
1.7 cm. cSCC lesions were located on the face (54/111; 48.6%), 
extremities (18/111; 16.2%), lip (15/111; 13.5%), scalp (14/111; 
12.6%) and ear (10/111; 9.0%). In addition, the results of the 
histological grading (18) demonstrated that 41 cases (36.9%) 
were well differentiated (WD), 62 cases (55.9%) were moder-
ately differentiated (MD) and 8 cases (7.2%) were poorly 
differentiated (PD). In addition, none of the patients included 
in this study presented lymph node metastasis or distant 
metastasis.
AXIN2 and SNAIL expression in cSCC tissue samples. 
AXIN2, which is a scaffolding protein, was mostly found in 
the cytoplasm of cancer cells in cSCC tissues. In addition, 
the results demonstrated that AXIN2 expression was low 
in 76 (68.5%) and high in 35 (31.5%) cSCC tissues. SNAIL, 
which is a transcription factor, was found in the cytoplasm and 
the nucleus of cSCC cells. Furthermore, SNAIL expression 
was low in 67 (60.4%) and high in 44 (39.6%) cSCC tissues 
(Table I). Representative expression patterns for AXIN2 and 
SNAIL IHC are presented in Fig. 1.
A significant association was identified between AXIN2 
and SNAIL expression in cSCC tissues. In addition, high 
SNAIL expression was detected in 62.9% cSCC tissues with 
high AXIN2 expression. By contrast, in cSCC tissues with low 
AXIN2 expression, only 28.9% exhibited high SNAIL expres-
sion (Fig. 2A; P=0.001).
Clinicopathological significance of AXIN2 and SNAIL 
expression in patients with cSCC. High expression levels 
of AXIN2 and SNAIL were more frequently detected in 
patients with recurrence (55.6 and 61.1%, respectively) 
compared with patients without recurrence (26.9 and 
35.5%, respectively; P=0.017 and P=0.042, respectively; 
Fig. 2B and C). Furthermore, tumor size and AXIN2 and 
SNAIL expression levels were significantly associated in 
cSCC tissues (Table I). High expression levels of AXIN2 
and SNAIL were more frequently detected in patients with 
larger tumor size (41.8 and 49.1%, respectively) compared 
with patients with smaller tumor size (21.4 and 30.4%, 
respectively; P=0.021 and P=0.044, respectively; Table I). 
No significant association was identified between AXIN2 
and SNAIL protein expression levels and other clinico-
pathological characteristics, including age, sex, lesion site 
and differentiation (Table I).
Table I. Clinicopathological significance of AXIN2 and SNAIL expression in 111 patients with cutaneous squamous cell 
carcinoma.
 AXIN2, n (%) SNAIL, n (%)
 ------------------------------------------------------------------------ ------------------------------------------------------------------------
Variable Case number, n (%) Low High P-value Low High P-value
Age, years       
  ≤74  56 (50.5) 43 (76.8) 13 (23.2) 0.057 35 (62.5) 21 (37.5) 0.642
  >74  55 (49.5) 33 (60.0) 22 (40.0)  32 (58.2) 23 (41.8) 
Sex       
  Male 50 (45.0) 35 (70.0) 15 (30.0) 0.753 28 (56.0) 22 (44.0) 0.395
  Female 61 (55.0) 41 (67.2) 20 (32.8)  39 (63.9) 22 (36.1) 
Site       
  Scalp 14 (12.6) 7 (50.0) 7 (50.0) 0.317 9 (64.3) 5 (35.7) 0.773
  Face 54 (48.6) 36 (66.7) 18 (33.3)  32 (59.3) 22 (40.7) 
  Ear 10 (9.0) 7 (70.0) 3 (30.0)  5 (50.0) 5 (50.0) 
  Lip 15 (13.5) 13 (86.7) 2 (13.3)  11 (73.3) 4 (26.7) 
  Acral 18 (16.2) 13 (72.2) 5 (27.8)  10 (55.6) 8 (44.4) 
Size, cm       
  ≤1.7 56 (50.5) 44 (78.6) 12 (21.4) 0.021a 39 (69.6) 17 (30.4) 0.044a
  >1.7 55 (49.5) 32 (58.2) 23 (41.8)  28 (50.9) 27 (49.1) 
Differentiation       
  WD 41 (36.9) 27 (65.9) 14 (34.1) 0.099 25 (61.0) 16 (39.0) 0.824
  MD 62 (55.9) 46 (74.2) 16 (25.8)  38 (61.3) 24 (38.7) 
  PD 8 (7.2) 3 (37.5) 5 (62.5)  4 (50.0) 4 (50.0) 
Recurrence       
  Yes 18 (16.2) 8 (44.4) 10 (55.6) 0.017a 7 (38.9) 11 (61.1) 0.042a
  No 93 (83.8) 68 (73.1) 25 (26.9)  60 (64.5) 33 (35.5) 
aP<0.05. AXIN2, axis inhibition protein 2; MD, moderately differentiated; PD, poorly differentiated; WD, well differentiated.
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Figure 1. Representative expression patterns of AXIN2 and SNAIL proteins in cutaneous squamous cell carcinoma tissue samples. Magnification, x400. Scale bar, 
20 µm. Cytoplasmic expression of AXIN2 and cytoplasmic and nuclear expression of SNAIL were considered as positive patterns. AXIN2, axis inhibition protein 2.
Figure 2. AXIN2 and SNAIL expression in cSCC tissue samples. (A) AXIN2 expression was significantly associated with SNAIL expression in cSCC tissues 
(χ2 test, P=0.001). Recurrence occurred more frequently in patients with (B) high AXIN2 or (C) SNAIL expression compared with patients with low AXIN2 
or SNAIL expression (Fisher's exact test, P=0.017 and P=0.042, respectively). Patients with (D) larger tumors, (E) poorly differentiated histological grade, 
(F) high AXIN2 expression and (G) high SNAIL expression presented decreased recurrence-free survival rates (log-rank test, P=0.025, P<0.001, P=0.001 and 
P=0.001, respectively). AXIN2, axis inhibition protein 2; cSCC, cutaneous squamous cell carcinoma.
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Risk factors for recurrence in patients with cSCC. The 
results of the Kaplan-Meier curve analysis demonstrated 
that recurrence‑free survival was significantly associated 
with tumor size (P=0.025), differentiation status (P<0.001) 
and expression of AXIN2 (P=0.001) and SNAIL (P=0.001; 
Fig. 2D-G). In addition, poor recurrence-free survival was 
observed in patients with tumors of larger size (median 
survival duration of 13 months for tumor size ≤1.7 cm vs. 
8 months for tumor size >1.7 cm), PD histological grade 
(median survival duration of 12.0 and 11.0 months for WD 
and MD histological grades, respectively, and of 8.0 months 
for patients with PD histological grade), high AXIN2 
expression (median survival duration of 16.0 months for low 
AXIN2 expression vs. 6.0 months for high AXIN2 expres-
sion) or high SNAIL expression (median survival duration 
of 13.0 months for low SNAIL expression vs. 8.0 months for 
high SNAIL expression). According to the American joint 
Committee on Cancer (8th edition) (19), tumor diameter 
>2 cm is the main cutoff value for tumor size (19,20). In the 
present study, no association was identified between tumor 
size and recurrence‑free survival when using the 2 cm tumor 
size cut‑off value. However, the median tumor size cutoff 
of 1.7 cm was more predictive of cumulative disease-free 
survival rate (Fig. 2D; P=0.025). This difference in the cutoff 
value of tumor size may be due to the difference between 
MMS and other surgical methods.
The results of the Cox-regression analysis demonstrated 
that age [hazard ratio (HR), 0.955; 95% confidence interval 
(CI), 0.914-0.999; P=0.043], high AXIN2 expression (HR, 
15.169; 95% CI, 3.149-73.072; P=0.001) and high SNAIL 
expression (HR, 4.795; 95% CI, 1.329-17.296; P=0.045) 
were independent risk factors for recurrence-free survival in 
patients with cSCC (Table II).
Construction of a predictive nomogram. Predictive nomo-
grams were constructed using patients' clinicopathological 
characteristics and/or AXIN2 and SNAIL protein expression 
to analyze the 1‑, 2‑, 3‑ and 5‑year recurrence‑free survival in 
patients with cSCC. The c-index of the nomogram constructed 
with a combination of clinicopathological characteristics, 
including sex, age, lesion site, tumor size and differentiation, 
was ~0.40. When the nomogram was constructed using AXIN2 
and SNAIL protein expression, the c-index was ~0.69. When 
all clinicopathological characteristics and AXIN2 and SNAIL 
protein expression were combined, the c-index of the nomogram 
was ~0.61. Furthermore, the c-index increased to ~0.75 when 
the nomogram was constructed with independent risk factors 
such as age and expression of AXIN2 and SNAIL (Fig. 3).
To demonstrate the practical usage of the nomogram, a 
nomogram in Hypertext Markup Language (HTML) format 
that included predictive factors, total score and probabilities 
of recurrence-free survival was constructed (Fig. 4A). As 
presented in Fig. 4Aa, in a patient aged 54 years with low AXIN2 
and high SNAIL expression, the probability of recurrence-free 
survival calculated using the nomogram was 99, 92.5, 84.6 and 
77.6% after 1, 2, 3 and 5 years, respectively. By contrast, as 
presented in Fig. 4Ab, a 54-year-old patient with high AXIN2 
expression and low SNAIL expression presented a probability 
of recurrence-free survival of 82.8, 66.2, 54.3 and 35.5% after 
1, 2, 3 and 5 years, respectively. The constructed nomogram 
with the highest c-index was calibrated to further evaluate 
the association between the predicted probability and the real 
outcomes of patients with cSCC. The predicted outcomes are 
presented on the x-axis, and the actual data for recurrence-free 
survival of each patient with cSCC are presented on the y-axis. 
An ideal nomogram would demonstrate perfect consensus 
(x=y) between data predicted by the nomogram and actual 
recurrence-free survival for each patient in the cohort. The 
results of the present study demonstrated a relatively solid line, 
especially for the prediction of recurrence-free survival after 1 
and 2 years (Fig. 4B).
Discussion
Aberrant activation of the Wnt signaling pathway and 
subsequent initiation of EMT have been demonstrated to be 
associated with poor prognosis in various types of cancer, 
including cSCC (10,14,21). In the present study, the predictive 
value of the protein expression of two EMT genes, AXIN2 
and SNAIL, in the recurrence of cSCC was evaluated over a 
long-term follow-up period.
Wnt signaling is activated by binding of the Wnt ligand 
to its co-receptors, including seven-transmembrane-domain 
Frizzled receptors and a low‑density lipoprotein (LDL) 
receptor-related protein (LRP5/LRP6). In the absence of Wnt 
ligands, GSK3 assembles a β-catenin destruction complex and 
subsequently mediates β-catenin degradation (22). Previous 
studies reported that AXIN2 is a molecular component of the 
β-catenin destruction complex that can repress various down-
stream target genes of β-catenin, indicating its role as a tumor 
suppressor. However, when aberrant activation of the Wnt 
signaling pathway occurs, AXIN2 protein is translocated from 
the β-catenin destruction complex to the LRP5 receptor via 
the phosphorylated Dishevelled, leading to the inactivation of 
Table II. Risk factors for recurrence in patients with cutaneous 
squamous cell carcinoma.
Variable Hazard ratio (95% CI) P‑value
Sex 1.650 (0.492-5.533) 0.417
Age 0.955 (0.914-0.999) 0.043a
Lesion site  
  Scalp 1 
  Face 0.467 (0.104-2.101) 0.321
  Ear 0.802 (0.103-6.231) 0.833
  Lip 0.409 (0.069-2.425) 0.325
  Acral 0.451 (0.081-2.541) 0.364
  Size 1.119 (0.297‑4.213) 0.868
Differentiation  
  WD 1 
  MD 0.817 (0.241-2.769) 0.746
  PD 1.516 (0.303-7.582) 0.613
  SNAIL 4.795 (1.329-17.296) 0.045a
  AXIN2 15.169 (3.149-73.072) 0.001a
aP<0.05. CI, Confidence interval; MD, moderately differentiated; 
PD, poorly differentiated; WD, well differentiated.
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the β-catenin destruction complex. β-catenin is subsequently 
protected from the degradation process and further involved in 
the transcription of Wnt target genes (23,24).
Previous studies suggested that AXIN2 may serve onco-
genic roles. As one of the T-cell factor/lymphoid enhancer 
factor downstream targets of canonical Wnt signaling 
Figure 4. (A-a and A-b) HTML format for the nomogram presenting highest accuracy. HTML showed the total score and the associated 1-, 2-, 3- and 5-year 
RFS for patients with cSCC. (Ba-Bd) Calibration of the nomogram. An ideal nomogram would demonstrate perfect consensus (x=y) between data predicted 
by the nomogram and actual RFS for each patient in the cohort. The calibration of the nomogram demonstrated a relatively solid line, especially for the 
prediction of RFS after 1 and 2 years. AXIN2, axis inhibition protein 2; cSCC, cutaneous squamous cell carcinoma; HTML, Hypertext Markup Language; 
RFS, recurrence-free survival.
Figure 3. Nomogram for predicting the probability of RFS of cSCC patients. Probability of 1-, 2-, 3- and 5-year RFS for each patient with cSCC may be identi-
fied using the nomogram. AXIN2, axis inhibition protein 2; cSCC, cutaneous squamous cell carcinoma; RFS, recurrence‑free survival.
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pathway, AXIN2 has been demonstrated to be upregulated in 
various types of cancer, including hepatoblastoma, cervical, 
breast and colorectal cancer (10,25,26). Furthermore, a study 
has reported that AXIN2 upregulation mediates the increased 
nuclear SNAIL and β-catenin expression by supporting the 
nuclear export function of GSK-3 in breast cancer cells (10). 
In addition, the present study demonstrated that AXIN2 and 
SNAIL expression levels were significantly associated in cSCC 
tissues. A previous study reported that AXIN2 knockdown led 
to decreased invasive ability of colorectal cancer cells (15), 
whereas another study demonstrated that AXIN2 can induce 
genomic instability by influencing centrosome cohesion at the 
mitotic checkpoint (27). These findings suggested that AXIN2 
may act as an oncogene protein during cancer progression, but 
not as a tumor suppressor.
Consistent with observations in breast cancer (10), the 
results of the present study reported that SNAIL expression 
was more frequently detected in cSCC tissues with high 
AXIN2 expression compared with cSCC tissues with low 
AXIN2 expression. Furthermore, the results of the Cox regres-
sion analysis demonstrated that the expression of AXIN2 and 
SNAIL was an independent risk factor for recurrence-free 
survival in patients with cSCC. In particular, patients with 
high AXIN2 and SNAIL expression presented a higher risk 
of recurrence compared with patients with low AXIN2 and 
SNAIL expression or patients with high expression of AXIN2 
or SNAIL only. These results suggested that AXIN2-mediated 
SNAIL stabilization and aberrant activation of the Wnt 
signaling pathway may serve crucial roles in cSCC recurrence.
In the present study, certain clinicopathological characteris-
tics, including large tumor size and poor tumor differentiation, 
were also identified as risk factors for recurrence in patients with 
cSCC according to the Kaplan-Meier analysis. Furthermore, 
age was considered as an independent risk factor for recurrence 
in this study. However, when the nomogram was constructed 
using only clinicopathological characteristics, the prediction 
model accuracy was very low, the c-index of the nomogram 
was ~0.40. The accuracy was improved by considering the 
molecular markers as predictive factors. The c-index increased 
to ~0.75 when the clinicopathological characteristics were 
combined with AXIN2 and SNAIL expression. In addition, 
the results of the calibration plot also demonstrated that the 
nomogram exhibited a high level of predictive accuracy in 
patients with cSCC. Further identification of novel biomarkers 
related to cSCC pathogenesis are required in order to increase 
the prediction accuracy of the nomogram.
Since AXIN2 is a target of the canonical Wnt signaling 
pathway, the results of the present study suggested that acti-
vation of the canonical Wnt signaling pathway and EMT 
progression may be involved in cSCC recurrence. In addition, 
AXIN2 and SNAIL expression may be considered as potential 
predictive biomarkers for assessing the risk of recurrence in 
patients with cSCC.
The present study had limitations. Certain important 
clinical characteristics, including previous history of organ 
transplantation, diabetes mellitus and other cancers, were 
excluded from analysis as they were missing in >50% patients. 
The predictive nomogram constructed in the present study 
may therefore not be fully performant. However, to the best of 
our knowledge, the present study described the first prediction 
model that may be used to investigate the risk of recurrence in 
patients with cSCC following MMS.
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